pubmed-article:1331764 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:1331764 | lifeskim:mentions | umls-concept:C0007452 | lld:lifeskim |
pubmed-article:1331764 | lifeskim:mentions | umls-concept:C1135918 | lld:lifeskim |
pubmed-article:1331764 | lifeskim:mentions | umls-concept:C0034052 | lld:lifeskim |
pubmed-article:1331764 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
pubmed-article:1331764 | lifeskim:mentions | umls-concept:C1171362 | lld:lifeskim |
pubmed-article:1331764 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
pubmed-article:1331764 | lifeskim:mentions | umls-concept:C1515670 | lld:lifeskim |
pubmed-article:1331764 | pubmed:issue | 5 | lld:pubmed |
pubmed-article:1331764 | pubmed:dateCreated | 1992-12-9 | lld:pubmed |
pubmed-article:1331764 | pubmed:abstractText | Bovine pulmonary artery smooth muscle (SM) cells express a novel 5-hydroxytryptamine (5-HT) (5-HT4-like) receptor coupled to cAMP accumulation. cAMP radioimmunoassay established the agonist and antagonist profiles of this receptor. 5-HT (EC50 = 91 +/- 33 nM) and 5-methoxytryptamine were equipotent at the SM cell 5-HT receptor and both were more potent than 5-carboxamidotryptamine. Other tryptamine derivatives were less potent but remained full agonists. These findings are consistent with previous reports regarding 5-HT4 and 5-HT4-like receptors in the central nervous system. The most potent antagonists were the antidepressant compounds nortriptyline (IC50 = 177 +/- 153 nM) and zimelidine (IC50 = 202 +/- 101 nM). The 5-HT3 and 5-HT4 antagonist 3-tropanyl-indole-3-carboxylate (ICS 205-930) was also a competitive antagonist at this 5-HT4-like receptor (pA2 = 6.3). Antagonist affinities differed slightly at the SM cell receptor, compared with other 5-HT4 and 5-HT4-like receptors in the central nervous system. Nonetheless, the SM cell 5-HT4-like receptor displayed the same differential antagonist potencies as reported for these other receptors (ICS 205-930 > MDL 72222 and mianserin > ketanserin). 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) was the most potent agonist for this 5-HT4-like receptor (EC50 = 6.4 +/- 3.4 nM). 8-OH-DPAT-induced cAMP accumulation could be blocked by ICS 205-930 but not by the 5-HT1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-pthalimido)butyl]piperazine hydrobromide, distinguishing the SM cell 5-HT receptor from 5-HT1A receptors. The mechanism of 5-HT-stimulated cAMP production was also investigated. First, GTP augmented basal and 5-HT-stimulated cAMP accumulation. Second, antisera to the carboxyl terminus of the alpha subunit of Gs, attenuated 5-HT-mediated adenylate cyclase activation. This established that 5-HT-stimulated cAMP accumulation in SM cells required GS. These findings suggest that SM cells express a novel 5-HT4-like receptor positively coupled to adenylate cyclase. An unexpected finding was that 8-OH-DPAT is a potent partial agonist. These studies suggest that there may be heterogeneity among 5-HT4-like receptors. | lld:pubmed |
pubmed-article:1331764 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1331764 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1331764 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1331764 | pubmed:language | eng | lld:pubmed |
pubmed-article:1331764 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1331764 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:1331764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1331764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1331764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1331764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1331764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1331764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1331764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1331764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1331764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1331764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1331764 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:1331764 | pubmed:month | Nov | lld:pubmed |
pubmed-article:1331764 | pubmed:issn | 0026-895X | lld:pubmed |
pubmed-article:1331764 | pubmed:author | pubmed-author:LeeS LSL | lld:pubmed |
pubmed-article:1331764 | pubmed:author | pubmed-author:FanburgB LBL | lld:pubmed |
pubmed-article:1331764 | pubmed:author | pubmed-author:AlbertF IFI | lld:pubmed |
pubmed-article:1331764 | pubmed:author | pubmed-author:GettysT WTW | lld:pubmed |
pubmed-article:1331764 | pubmed:author | pubmed-author:RaymondJ RJR | lld:pubmed |
pubmed-article:1331764 | pubmed:author | pubmed-author:MiddletonJ... | lld:pubmed |
pubmed-article:1331764 | pubmed:author | pubmed-author:OlsenC LCL | lld:pubmed |
pubmed-article:1331764 | pubmed:author | pubmed-author:BeckerB NBN | lld:pubmed |
pubmed-article:1331764 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:1331764 | pubmed:volume | 42 | lld:pubmed |
pubmed-article:1331764 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:1331764 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:1331764 | pubmed:pagination | 817-25 | lld:pubmed |
pubmed-article:1331764 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
pubmed-article:1331764 | pubmed:meshHeading | pubmed-meshheading:1331764-... | lld:pubmed |
pubmed-article:1331764 | pubmed:meshHeading | pubmed-meshheading:1331764-... | lld:pubmed |
pubmed-article:1331764 | pubmed:meshHeading | pubmed-meshheading:1331764-... | lld:pubmed |
pubmed-article:1331764 | pubmed:meshHeading | pubmed-meshheading:1331764-... | lld:pubmed |
pubmed-article:1331764 | pubmed:meshHeading | pubmed-meshheading:1331764-... | lld:pubmed |
pubmed-article:1331764 | pubmed:meshHeading | pubmed-meshheading:1331764-... | lld:pubmed |
pubmed-article:1331764 | pubmed:meshHeading | pubmed-meshheading:1331764-... | lld:pubmed |
pubmed-article:1331764 | pubmed:meshHeading | pubmed-meshheading:1331764-... | lld:pubmed |
pubmed-article:1331764 | pubmed:meshHeading | pubmed-meshheading:1331764-... | lld:pubmed |
pubmed-article:1331764 | pubmed:meshHeading | pubmed-meshheading:1331764-... | lld:pubmed |
pubmed-article:1331764 | pubmed:meshHeading | pubmed-meshheading:1331764-... | lld:pubmed |
pubmed-article:1331764 | pubmed:meshHeading | pubmed-meshheading:1331764-... | lld:pubmed |
pubmed-article:1331764 | pubmed:meshHeading | pubmed-meshheading:1331764-... | lld:pubmed |
pubmed-article:1331764 | pubmed:meshHeading | pubmed-meshheading:1331764-... | lld:pubmed |
pubmed-article:1331764 | pubmed:meshHeading | pubmed-meshheading:1331764-... | lld:pubmed |
pubmed-article:1331764 | pubmed:meshHeading | pubmed-meshheading:1331764-... | lld:pubmed |
pubmed-article:1331764 | pubmed:meshHeading | pubmed-meshheading:1331764-... | lld:pubmed |
pubmed-article:1331764 | pubmed:year | 1992 | lld:pubmed |
pubmed-article:1331764 | pubmed:articleTitle | 8-hydroxy-2-(di-n-propylamino)tetralin-responsive 5-hydroxytryptamine4-like receptor expressed in bovine pulmonary artery smooth muscle cells. | lld:pubmed |
pubmed-article:1331764 | pubmed:affiliation | Medical Service (Nephrology), Department of Veterans Affairs Medical Center, Durham, North Carolina 27705. | lld:pubmed |
pubmed-article:1331764 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:1331764 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
pubmed-article:1331764 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
pubmed-article:1331764 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1331764 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1331764 | lld:pubmed |